Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | MAP2K1 | Q02750 | 4/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.31 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.31 |
| ▸ | IARS2 | Q9NSE4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13247500 | 0.97 | LMNA (0.63) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL13247519 | 0.96 | LMNA (0.62) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL13882424 | 0.95 | LMNA (0.61) | LMNACYP2C19HIF1AMAP2K1 | |
| SCHEMBL3057502 | 0.95 | LMNA (0.63) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL13246452 | 0.94 | LMNA (0.67) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL13247488 | 0.94 | LMNA (0.67) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL13959827 | 0.92 | LMNA (0.58) | LMNACYP2C19HIF1A | |
| SCHEMBL13247602 | 0.92 | LMNA (0.65) | LMNACYP2C19HIF1A | |
| SCHEMBL9352758 | 0.90 | LMNA (0.77) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL13246462 | 0.90 | LMNA (0.74) | LMNACYP2C19HIF1AEGFRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202511-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-06-19 | — | — | US | disclosed |
| US-8202511-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-06-19 | — | — | US | disclosed |
| US-20100221189-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-09-02 | — | — | US | disclosed |
| US-20100221189-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100221189-A1 | CONTRAST AGENTS | NR1I3, NR1I2, NR1D2 | LMNA 2753/4885CYP2C19 754/4885HIF1A 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.